Manages anxiety disorders. ANDA 84769, held by Barr. Chlordiazepoxide Hydrochloride.
As of Nov 16, 2026, ANDA 84769 (Chlordiazepoxide Hydrochloride), held by Barr, was first approved by FDA on Jun 10, 1976, with 28 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Chlordiazepoxide HCl capsules are indicated for the management of anxiety disorders or for the short term relief of symptoms of anxiety, withdrawal symptoms of acute alcoholism, and preoperative apprehension and anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of chlordiazepoxide HCl capsules in long term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 10, 1976 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Chlordiazepoxide Hydrochloride25MG · capsule;oral | Chlordiazepoxide Hydrochloride | RxReference drug |
| Jan 17, 2023 | Supplement 98Labeling · Standard review | Approved | None posted |
| Feb 5, 2021 | Supplement 96Labeling · Standard review | Approved | None posted |
| Dec 16, 2016 | Supplement 92Labeling · Standard review | Approved | None posted |
| Dec 4, 2001 | Supplement 88Manufacturing | Approved | None posted |
| Nov 2, 2001 | Supplement 86Manufacturing | Approved | None posted |
| Jul 13, 2000 | Supplement 87Manufacturing | Approved | None posted |
| Dec 21, 1999 | Supplement 85Manufacturing | Approved | None posted |
| May 20, 1999 | Supplement 83Manufacturing | Approved | None posted |
| May 13, 1999 | Supplement 84Manufacturing | Approved | None posted |
| Dec 1, 1998 | Supplement 81Manufacturing | Approved | None posted |
| Nov 16, 1998 | Supplement 82Manufacturing | Approved | None posted |
| Apr 16, 1997 | Supplement 80Manufacturing | Approved | None posted |
| Aug 28, 1996 | Supplement 79Manufacturing | Approved | None posted |
| Dec 23, 1994 | Supplement 78Manufacturing | Approved | None posted |
| Aug 2, 1993 | Supplement 77Labeling | Approved | None posted |
| Apr 3, 1992 | Supplement 76Manufacturing | Approved | None posted |
| Apr 3, 1992 | Supplement 74Manufacturing | Approved | None posted |
| May 10, 1989 | Supplement 73Labeling | Approved | None posted |
| Jul 17, 1987 | Supplement 71Manufacturing | Approved | None posted |
| Jul 17, 1987 | Supplement 70Manufacturing | Approved | None posted |
| Mar 20, 1987 | Supplement 69Manufacturing | Approved | None posted |
| Jul 31, 1986 | Supplement 66Manufacturing | Approved | None posted |
| Jul 31, 1986 | Supplement 62Manufacturing | Approved | None posted |
| Jul 31, 1986 | Supplement 61Manufacturing | Approved | None posted |
| Jul 31, 1986 | Supplement 60Manufacturing | Approved | None posted |
| Mar 3, 1982 | Supplement 47Manufacturing | Approved | None posted |
| Oct 30, 1980 | Supplement 37Manufacturing | Approved | None posted |
| Jan 13, 1977 | Supplement 7Manufacturing | Approved | None posted |
| Jun 10, 1976 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters